COVID-19

Oncotelic has two pharmacological agents in clinical trials to manage Covid-19, the disease caused by the SARS-CoV-2 virus. OT-101 and ArtiVeda both work by inhibiting TGF-β to neutralize the SARS-CoV-2 virus.

Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications, the company tested OT-101 and Artemisinin, both of which showed potent activity in the lab and promising data for treating the virus infection and associated complications based on the their mechanism of action.

Mechanism of Action on TGF-Beta
Study TitleInterventionControlStatus
A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study of OT 101 in Hospitalized COVID-19 Subjects: C001 2020 01OT-101Standard of CareNot yet started
A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19: ARTI/WBPL/P4/2020/01 ArtiVedaStandard of CareEnrolling
Annals of Pulmonary and Critical Care Medicine. Medical Scientific Rationale for a Randomized, Placebo-Controlled, Phase 2 Study of Trabedersen/OT-101 in COVID-19 Patients with Hypoxemic Respiratory Failure by Dr. Fatih Unckun and Vuong TrieuOT-101Standard of CarePhase 2

ArtiVeda

ArtiVeda contains the Ayurveda Dvipaantara Damanaka, 500mg of Artemisia Powder.

It will be available in India at the end of December to treat Covid-19.

The main ingredient in ArtiVeda is Artemisinin which is derived from the plant species Artemisia and has been used medicinally to treat fevers, headache and inflammation for centuries in India and China.

We discovered that Artemisinin is highly potent at inhibiting the ability of the COVID-19 causing virus (SARS-CoV-2) to multiply while also having an excellent safety index. Our results indicate that Artemisinin has an EC50 of 0.45 ug/ml and Safety Index of 140.

As a TGF-β inhibitor ArtiVeda should target multiple viral threats including Covid-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. With treatment, viral replication is suppressed, IFNβ is induced and innate and adaptive immune responses are suppressed.  The end result is protection from both viral and immune driven pathologies (ARDS and cytokine storm).

Oncotelic is working with distributors in low and middle income countries to provide a clean supply to help manage this humanitarian crisis.

A similar product, ArtiShield will be marketed outside of India.

OT-101

OT-101 has a similar mechanism of action as ArtiVeda, and will soon enter into clinical trials.

Copyright © 2020 Onteclic Therapeutics Inc., a TGF ImmunoOncology Company. All rights reserved.